Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Polycythemia Vera × bomedemstat × Clear all

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 18 Peripheral Blood Stem Cell Transplantation 16 Cyclophosphamide 15 ruxolitinib 13 Busulfan 12 Whole-Body Irradiation 8 Tacrolimus 8 Mycophenolic Acid 8 Antilymphocyte Serum 7 Etoposide 6 Cytarabine 6 Cyclosporine 6 peginterferon alfa-2a 5 fludarabine 5 Methotrexate 5 Melphalan 5 Filgrastim 5 Aspirin 5 Prednisone 4 Hydroxyurea 4 Decitabine 4 givinostat hydrochloride 3 givinostat 3 Radiotherapy 3 Lenalidomide 3 Imatinib Mesylate 3 tipifarnib 2 thymoglobulin 2 sonidegib 2 pomalidomide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05558696 2025-07-29

MK-3543-004

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon ⚡